Latest News and Press Releases

NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production

NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events